

Shu-Hsing Cheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5389782/publications.pdf>

Version: 2024-02-01

55
papers

1,344
citations

567144

15
h-index

395590

33
g-index

59
all docs

59
docs citations

59
times ranked

3332
citing authors

#	ARTICLE	IF	CITATIONS
1	Nationwide surveillance of antimicrobial resistance in invasive isolates of <i>Streptococcus pneumoniae</i> in Taiwan from 2017 to 2019. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 215-224.	1.5	5
2	In-vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> isolates associated from bloodstream infection in Taiwan between 2018-2020. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 888-895.	1.5	15
3	Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2. <i>Theranostics</i> , 2022, 12, 1-17.	4.6	6
4	Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV. <i>Viruses</i> , 2022, 14, 439.	1.5	5
5	Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections. <i>World Journal of Gastroenterology</i> , 2022, 28, 1172-1183.	1.4	5
6	Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 766-777.	0.8	22
7	An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901. <i>Vaccines</i> , 2022, 10, 655.	2.1	11
8	Anti-Spike Antibody Response to Natural Infection with SARS-CoV-2 and Its Activity against Emerging Variants. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	3
9	Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. <i>PLoS Pathogens</i> , 2021, 17, e1009352.	2.1	56
10	Multicenter evaluation of four immunoassays for the performance of early diagnosis of COVID-19 and assessment of antibody responses of patients with pneumonia in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 816-829.	1.5	8
11	Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study. <i>Infectious Diseases and Therapy</i> , 2021, 10, 827-838.	1.8	4
12	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. <i>Nature Communications</i> , 2021, 12, 2349.	5.8	194
13	Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 473-481.	0.9	13
14	Clinical validation of an automated reverse transcription-insulated isothermal PCR assay for the detection of severe acute respiratory syndrome coronavirus 2. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 522-526.	1.5	8
15	Antimicrobial susceptibility of bacteremic vancomycin-resistant <i>Enterococcus faecium</i> to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019-2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART). <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106353.	1.1	7
16	Predicting Emotional Valence of People Living with the Human Immunodeficiency Virus Using Daily Voice Clips: A Preliminary Study. <i>Healthcare (Switzerland)</i> , 2021, 9, 1148.	1.0	1
17	Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106403.	1.1	3
18	In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106377.	1.1	12

#	ARTICLE	IF	CITATIONS
19	Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29%900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. <i>Lancet HIV</i> ,the, 2021, 8, e531-e543.	2.1	77
20	National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive <i>Streptococcus pneumoniae</i> isolates in adults: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2017-2020. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 26, 308-316.	0.9	9
21	Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. <i>Lancet Respiratory Medicine</i> ,the, 2021, 9, 1396-1406.	5.2	105
22	National Surveillance of Antimicrobial Susceptibility of Bacteremic Gram-Negative Bacteria with Emphasis on Community-Acquired Resistant Isolates: Report from the 2019 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART). <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	15
23	Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 950-958.	3.6	268
24	Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan. <i>Emerging Microbes and Infections</i> , 2020, 9, 2157-2168.	3.0	38
25	A case of transient existence of SARS-CoV-2 RNA in the respiratory tract with the absence of anti-SARS-CoV-2 antibody response. <i>International Journal of Infectious Diseases</i> , 2020, 96, 464-466.	1.5	15
26	Rapid establishment of a COVID-19 biobank in NHRI by National Biobank Consortium of Taiwan. <i>Biomedical Journal</i> , 2020, 43, 314-317.	1.4	14
27	Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 488-492.	1.5	68
28	A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). <i>PLoS ONE</i> , 2020, 15, e0242763.	1.1	65
29	Characteristics of HIV-positive pregnant women and HIV- and antiretroviral therapy-exposed fetuses: A case-control study. <i>Journal of Infection in Developing Countries</i> , 2020, 14, 901-907.	0.5	3
30	Title is missing!. , 2020, 15, e0242763.		0
31	Title is missing!. , 2020, 15, e0242763.		0
32	Title is missing!. , 2020, 15, e0242763.		0
33	Title is missing!. , 2020, 15, e0242763.		0
34	Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 865-871.	1.5	2
35	<p>Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial<p>. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 937-945.	1.1	5
36	Nationwide surveillance of antimicrobial resistance among clinically important Gram-negative bacteria, with an emphasis on carbapenems and colistin: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2018. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 318-328.	1.1	41

#	ARTICLE	IF	CITATIONS
37	Early Seroreversion After 2 Doses of Hepatitis A Vaccination in Human Immunodeficiency Virus-Positive Patients: Incidence and Associated Factors. <i>Hepatology</i> , 2019, 70, 465-475.	3.6	20
38	Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 556-562.	1.5	15
39	Clinical features of acute human immunodeficiency virus infection in Taiwan: A multicenter study. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 700-709.	1.5	10
40	Human papillomavirus infection and anal cytology in Taiwanese homosexual men with and without HIV infection. <i>Journal of Infection in Developing Countries</i> , 2019, 13, 318-325.	0.5	5
41	Multiple types of human papillomavirus infection and anal precancerous lesions in HIV-infected men in Taiwan: a cross-sectional study. <i>BMJ Open</i> , 2018, 8, e019894.	0.8	10
42	Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 849-859.	1.1	9
43	Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan. <i>PLoS ONE</i> , 2018, 13, e0194149.	1.1	14
44	Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up. <i>PLoS ONE</i> , 2017, 12, e0179870.	1.1	31
45	Evolution of hepatitis A virus seroprevalence among HIV-positive adults in Taiwan. <i>PLoS ONE</i> , 2017, 12, e0186338.	1.1	13
46	Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan. <i>PLoS ONE</i> , 2017, 12, e0171596.	1.1	20
47	Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients. <i>Journal of Infection and Chemotherapy</i> , 2016, 22, 744-747.	0.8	6
48	Oncogenic human papillomavirus is not helpful for cytology screening of the precursor lesions of anal cancers in Taiwanese men who are infected with human immunodeficiency virus. <i>International Journal of Clinical Oncology</i> , 2015, 20, 943-951.	1.0	18
49	Antiretroviral therapy (ART) management of Low-Level Viremia in Taiwan (ALLEVIATE). <i>Journal of the International AIDS Society</i> , 2014, 17, 19785.	1.2	4
50	Lipid-lowering agents for dyslipidemia in patients who were infected with HIV in Taoyuan, Taiwan. <i>Journal of the International AIDS Society</i> , 2014, 17, 19556.	1.2	4
51	Screening and risk factors for anal cancer precursors in men infected with HIV in Taiwan. <i>Journal of Medical Virology</i> , 2014, 86, 193-201.	2.5	14
52	Skin rash related to once-daily boosted darunavir-containing antiretroviral therapy in HIV-infected Taiwanese: Incidence and associated factor. <i>Journal of Infection and Chemotherapy</i> , 2014, 20, 465-470.	0.8	6
53	Safety of rilpivirine plus nucleoside reverse-transcriptase inhibitors in HIV-infected Taiwanese with a higher prevalence of hepatitis virus infection. <i>Journal of the International AIDS Society</i> , 2014, 17, 19580.	1.2	1
54	Highly Active Antiretroviral Therapy is Associated with Decreased Incidence of Sexually Transmitted Diseases in a Taiwanese HIV-Positive Population. <i>AIDS Patient Care and STDs</i> , 2013, 27, 155-162.	1.1	6

#	ARTICLE	IF	CITATIONS
55	Influence of age and CD4+ T cell counts on the prevalence of genital human papillomavirus infection among HIV-seropositive men who have sex with men in Taiwan. <i>Journal of Medical Virology</i> , 2012, 84, 1876-1883.	2.5	11